+44 (0)1865-842-976 (UK)

+91 20 30108 270 (ASIA)

The next big question in cancer immunotherapy is what’s next in immune-oncology? Overcoming resistance to various combinatorial approaches, selecting the patients and developing translational hypothesis besides designing optimal preclinical models for immunological agents, different strategies to regulate the microbiome are some of the major challenges faced by cancer research experts in the US.

There have been remarkable advancements in cancer immunotherapy especially in the clinical development of immune checkpoint inhibitors, neoantigen-based immunotherapy and microbiome-derived immunotherapy in cancer. One of the most promising approach in terms of ACT (Adoptive Cell Transfer) is the CAR-T cell therapy which has recently received its second approval from the FDA.

Following the success of our UK Edition, MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress-US Edition to be held on 21st and 22nd June 2018 in Philadelphia, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiome-derived immunotherapy and new paradigms in immune checkpoint inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

conference Registration Form



Academic Delegate$499
Industry Delegate $999
Solution Provider Delegate$1499


Key Highlights:

  • Neoantigens in personalized Cancer Immunotherapy
  • Immune Checkpoint Inhibitors and Combinations (PD-1, PD-L1, PD-L4)
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)
  • Neoantigen Discovery by Next-Generation Sequencing
  • Biomarkers and Cancer Vaccines
  • CAR-T cell therapy, Dendritic Cell Therapy
  • Microbiome in Cancer Immunotherapy (Targets and Challenges)
  • Oncolytic viruses
  • Tumor associated Macrophages as treatment in IO
  • Technologies for personalized TCR engineered cancer immunotherapies
  • Tumor microenvironment

For more information on the agenda of the conference, you can write to us at amit.shelke@marketsandmarkets.com

Who Should Attend ?

Who Should Attend?

From Pharmaceuticalbiopharmaceutical, biotechnology, hospitals and research institutes:

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group leaders, Clinicians, Professor, Assistant professors, Research fellow, PhD working on

Neoantigens and Microbiome

Cellular Therapy

Immune Checkpoint Inhibitors

  • Neoantigen-based therapies
  • Tumour antigens
  • Tumour immunotherapy
  • Neoepitopes
  • Cancer Vaccines
  • Cancer biomarkers
  • Tumour microenvironment
  • Clinical microbiology
  • Immunology
  • Microbiome/microbial genomics
  • Preclinical and Translational IO
  • Cell-Based Immunotherapies
  • Innate and adaptive immune cells
  • Tumour antigens and neoantigens
  • Cell and gene therapy
  • CAR-T cell therapy
  • T-cell receptors



  • Cancer immunotherapy
  • Immune checkpoint targets
  • Checkpoint inhibition
  • Cellular therapy
  • Clinical research
  • Combination therapy
  • Cancer Vaccines
  • Preclinical and Translational OncologyR&D
  • Immune biomarkers
  • Immunology
  • Cancer biology
  • Immuno-oncology
  • Tumour-associated mechanisms of immune suppression




  • Stefan Gluck

    Vice President, Global Medical Affairs, Solid Tumors, Immuno-Oncology and Early Assets, Celgene, Philadelphia, USA
  • Robert Iannone

    Senior Vice President, Head, Immuno-Oncology, AstraZeneca, Philadelphia, USA
  • Eugene Zhukovsky

    CSO, Biomunex Pharmaceuticals, France
  • Roy Baynes

    Senior Vice President, Chief Medical Officer, Head of Global Clinical Development, Merck Research Laboratories, New Jersey, USA
  • Stephen Schoenberger

    Professor of Immunology, La Jolla Institute for Allergy and Immunology, San Diego, USA
  • Laura Johnson

    Senior Director, Head Translational Medicine, Oncology Cell Therapy, GSK, Philadelphia, USA
  • Rakesh Dixit

    Vice President, R&D, MedImmune, USA
  • John Delaney

    Executive Director, Research, Amgen, USA
  • Andrew Allen

    CEO, Gritstone Oncology, USA
  • Ezio Bonvini

    Senior Vice President, CSO, MacroGenics, USA
  • Pranab Mukherjee

    Associate Professor, Case Western Reserve University, USA
  • Steve Doberstein

    Nektar Therapeutics, Senior Vice President, CSO, USA
  • Pramod Srivastava

    Director of the Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut, USA
  • Daniel Levey

    Senior Director Vaccine Research, Agenus, Boston, USA
  • Liang Deng

    Physician-Scientist, Dermatologist, Memorial Sloan Kettering Cancer Center, USA
  • Shahram Salek-Ardakani

    Director, Cancer Immunology, Pfizer, San Diego, USA
  • Tony Polverino

    Chief Scientific Officer, Kite Pharma, USA
  • Terry Fisher

    Director, Translational Science & Bioanalytical, Vaccinex, USA
  • Aiman Shalabi

    Chief Medical Officer, ,Cancer Research Institute, New York, USA
  • Ellen Pure

    Professor and Chair, Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, USA
  • Carl Morrison

    Executive Director of the Center for Personalized Medicine, Roswell Park Cancer Institute, New York, USA
  • Daniel O' Connor

    CEO, OncoSec, USA
  • John Castle

    Achilles Therapeutics, Chief Scientific Officer, USA
  • Moitreyee Chatterjee-Kishore

    Senior Director, Compound Development Team Leader Oncology, Janssen Pharmaceuticals, Philadelphia, USA
  • Joost Oppenheim

    Head, Cellular Immunology Section, NIH, USA
  • Christophe Queva

    Chief Scientific Officer, Oncorus, USA
  • Roderick O'Connorr

    University of Pennsylvania, Senior Research Investigator, USA
  • Ashok Shrivastava

    Cure Pharmaceuticals, Inc, CEO, USA
  • Eytan Barnea

    BioIncept LLC, Founder and Chief Scientist, USA
  • Patrick Hanley

    Director, GMP for Immunotherapy, Assistant Professor, Children’s National Medical Centre, USA
  • Sidharth Kerkar

    Head, Cancer Immunology Discovery Biomarkers, Boehringer Ingelheim, USA
  • Wei Zhou

    Senior Research Scientist, The Jackson Laboratory, USA


PBL Assay Science

A trusted source of high quality ELISAs, interferons, cytokines, and monoclonal antibodies, PBL Assay Science also specializes in exceptional services such as ultra-sensitive protein biomarker detection, multiplex biomarker assays and screening, and an extensive range of cell-based assays. Whether characterizing your compounds in activity assays, serving as a CRO for confirmatory assays or novel assay development, or expressing, purifying, and characterizing a novel protein or antibody, PBL is here to serve your needs.


Mitra Biotech

Mitra Biotech 

Mitra Biotech s a global leader in advancing truly personalized oncology treatment. The company’s CANscript™ platform recreates a patient’s own tumor microenvironment in vitro, measures multiple parameters to determine whether a tumor is responding to customer selected treatments, and then converts these parameters into a single score that predicts clinical response to each of the customer selected therapies.CANscript delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and support more effective and efficient cancer drug development

nebion NEBION

NEBION is a science-drive Swiss company that commercializes Genevestigator®, the premier platform for transcriptomic meta-analysis of public and private data. What customers appreciate the most is the high quality of curated data in combination with the user-friendly data mining tools, which enables them to boost their research by for
instance identifying novel drug targets and bio-markers more efficiently.
Besides the constant customer-driven expansion and development of Genevestigator®, NEBION offers data analysis services and bioinformatics consulting.

MBL MBL International Corporation (MBLI)

MBL International Corporation (MBLI) is a leading life science company focused on providing high quality, innovative, solutions-based products for both life science research and clinical diagnostics. MBLI has a focus on immuno-oncology, which includes providing reagents for assessing proliferation, for apoptosis at various stages, for the measurement of cytokines and interleukins, biomarkers of immune activation and immune suppression.  MBLI offers kits, antibodies, MHC tetramers, monomers, functionalized beads to meet the needs of researchers and scientists in this field. MBLI also develops, manufactures, and markets a broad portfolio of monoclonal and polyclonal fluorescent and recombinant proteins and ELISA kits


Lonza’s Bioscience Solutions

Lonza’s Bioscience Solutions- provider of  primary Clonetics and Poietics cells and media, Nucleofector™ Technology for difficult-to- transfect cells, CRISPR/Cas9, CAR-T Therapy,  Large Volume scale- up, Protein production, novel 3D culture methods and live-cell imaging system.
Provider of Endotoxin Detection Assays, Rapid Microbial Detection Technology, products , FlashGel™ System, PAGEr™ Precast Gels, and SeaKem™ Agarose Lonza is well-recognized for its outstanding scientific support team, and dedication to consistent, high performing products.

ACEAACEA Biosciences

ACEA Biosciences, The Cell Analysis Company, is a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. Advancing cancer immunotherapy research from the bench to the clinic requires reliable tools to translate in vitro results for use in vivo.  The xCELLigence® Real Time Cell Analysis instruments and NovoCyte® benchtop flow cytometer are furthering the development of cancer immunotherapeutics by providing a more complete and nuanced view of cancer cell behavior. Founded in San Diego, CA, in 2002, more than 2300 instruments have been placed globally, and over 1300 peer-reviewed publications have cited ACEA Biosciences technologies.


 MedGenome Inc

MedGenome Inc. is a global leader in genomics research and a superior partner to pharma/biotech companies and academic research institutions specializing in their immuno-oncology, diabetes, ocular diseases and general NGS services.

ACDAdvanced Cell Diagnostics

Advanced Cell Diagnostics – a Bio-Techne Brand, is a world leader in RNA biomarker analysis for precision medicine, providing the most advanced RNA analysis solutions for cell and tissue based research, drug discovery/development and diagnostics in molecular pathology. Its proprietary award-winning RNAscope® technology is capable of detecting and quantifying RNA biomarkers with single-molecule sensitivity and single-cell resolution. This technology has been cited in over 1000 peer-reviewed publications by a rapidly growing user base.




Cytek provides flow cytometry tools scientists require at prices they can afford including innovative technologies for high dimensional applications. Our newest flow cytometer, the CytekTM Aurora, is an affordable system uniquely suited for immuno-oncology applications from low to high complexity (>20 colors).   The unique technology onboard also enables flexibility in reagent choice, panel design, and applications, all with an intuitive workflow.  Come see the Cytek Aurora at our booth and learn more.


MarketsandMarkets provides a variety of direct and indirect marketing and networking opportunities for sponsors and exhibitors. 



All refreshment breaks and lunches take place in the main exhibition ensuring that exhibitors enjoy maximum time to meet and network with senior level attendees. 

Speaking and Workshop Opportunities

  • 15 minute small company showcase presentations.
  • 30 minute presentations on the main conference programme.
  • 25 minute satellite symposiums.
  • 60 minute presentation/workshop on the main conference programme.

Please enquire for pre and post events workshop options. 

Pre-arranged One-on-One Meetings

Prearranged one-on-one meetings ensure that you have personal time with your choice of delegates. Twenty-minute meetings take place during refreshment breaks. Full delegate profiles are provided prior to the conference to ensure that onsite, you meet with relevant delegates who are truly interested in your products and services. Meetings can take place on your exhibition or in your own private meeting area. 

Pre-event Support

MnM Conferences provide full service pre-event marketing and branding support. Opportunities available include: 

  • Your logo and company description on the event website.
  • Your logo on all marketing materials as a sponsor.
  • Pre-event email shots to attending delegates to increase your onsite exposure.
  • Articles about your products and services in our monthly event newsletter.

For sponsorship opportunities please contact us at events@marketsandmarkets.com

Mitra Biotech

Mitra Biotech

Media partners


All Poster presentations will take place in breaks and alongside the breakout sessions of the congress.  All the presentation will be displayed in a dedicated area along with accepted posters from both industry & vendor delegates.

To present a poster the presenter should be registered as a delegate and the poster space will be assigned on a first come first basic (Subjected to successful registration & space availability)In order to present a poster at the forum you need to be registered as a delegate.

Please note that there is limited space available and posters space is assigned on a first come first served basis (subject to checks and successful registration).

Posters should be presented as A0 or US equivalent, size E (841mm x 1189mm or 34 x 44 inches respectively) in portrait orientation.

Poster presentations are available to registered delegates only.

For further details and requirements please contact:

Email: events@marketsandmarkets.com

Academic delegatesFree
Industry and Solution Provider delegates$99

Posters Submission Form



Colorado BioScience Association

Colorado BioScience Association
 champions life science. The not-for-profit organization represents more than 350 member organizations and serves as the hub of Colorado’s thriving bioscience sector by connecting innovators to funding, infrastructure, research and talent. CBSA grows the bioscience workforce and leads business expansion policies to advance the industry in our state.

To support Next Gen Immuno-Oncology Congress, contact amit.shelke@marketsandmarkets.com


Next Gen Immuno-Oncology Congress will be held at the Radisson Hotel Philadelphia Northeast

Radisson Hotel Philadelphia Northeast
2400 Old Lincoln Hwy,
Feasterville-Trevose, PA 19053,

Hotel Booking Link

Accommodation is currently available at the Radisson Hotel Philadelphia Northeast at discounted rate. You will receive a link to book your accommodation via once you are fully registered. (Please note that we do not authorize any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than us regarding your accommodation requirements for this event, please let us know immediately on events@marketsandmarkets.com

About the Hotel

As an official hotel of Sesame Place theme park, Radisson Hotel Philadelphia Northeast is the perfect spot for families to rest and recharge in Trevose, PA. Near the intersection of US-1 and I-276 close to I-95, our location also gives you quick access to destinations like Historic Philadelphia, Parx Casino and the Philadelphia Mills mall. After a day of theme park shows and rides, grab a bite at our on-site restaurant and upload photos of your fun with free Wi-Fi. You can then relax on the sundeck while the kids splash in our indoor/outdoor pool.

For further information, please contact:

Email: events@marketsandmarkets.com